EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer

Yen-Nien Liu, Ming-Kun Liu, Yu-Ching Wen, Chien-Hsiu Li, Hsiu-Lien Yeh, Phan Vu Thuy Dung, Kuo-Ching Jiang, Wei-Hao Chen, Han-Ru Li, Jiaoti Huang, Wei-Yu Chen

Cancer Letters · 2024-08 · 598 · 217090

DOI: 10.1016/j.canlet.2024.217090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Yen-Nien Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Interleukin 1 Receptor Antagonist Protein, Prostatic Neoplasms, Cell Differentiation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor microenvironment (TME) of prostate cancer (PCa) is characterized by high levels of immunosuppressive molecules, including cytokines and chemokines. This creates a hostile immune landscape that impedes effective immune responses. The interleukin-1 (IL-1) receptor antagonist (IL1RN), a key anti-inflammatory molecule, plays a significant role in suppressing IL-1-related immune and inflammatory responses. Our research investigates the oncogenic role of IL1RN in PCa, particularly its interactions with muscarinic acetylcholine receptor 4 (CHRM4), and its involvement in driving immunosuppressive pathways and M2-like macrophage polarization within the PCa TME. We demonstrate that following androgen deprivation therapy (ADT), the IL1RN-CHRM4 interaction in PCa activates the MAPK/AKT signaling pathway. This activation upregulates the transcription factors E2F1 and MYCN, stimulating IL1RN production and creating a positive feedback loop that increases CHRM4 abundance in both PCa cells and M2-like macrophages. This ADT-driven IL1RN/CHRM4 axis significantly enhances immune checkpoint markers associated with neuroendocrine differentiation and treatment-resistant outcomes. Higher serum IL1RN levels are associated with increased disease aggressiveness and M2-like macrophage markers in advanced PCa patients. Additionally, elevated IL1RN levels correlate with better clinical outcomes following immunotherapy. Clinical correlations between IL1RN and CHRM4 expression in advanced PCa patients and neuroendocrine PCa organoid models highlight their potential as therapeutic targets. Our data suggest that targeting the IL1RN/CHRM4 signaling could be a promising strategy for managing PCa progression and enhancing treatment responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentInterleukin 1 Receptor Antagonist ProteinProstatic NeoplasmsCell DifferentiationMaleHumansCell Line, TumorSignal TransductionAnimalsAndrogen AntagonistsMacrophagesE2F1 Transcription Factor

Stichwörter der Autor:innen

Androgen deprivation therapyCHRM4IL1RNNeuroendocrine differentiationTumor microenvironment

Substanzen

Interleukin 1 Receptor Antagonist ProteinIL1RN protein, humanAndrogen AntagonistsE2F1 Transcription FactorE2F1 protein, human

Autor:innen und Institutionen

  • Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Urol…
  • Department of Urology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: 104…

Zitieren

APA

Liu, Y. N., Liu, M. K., Wen, Y. C., Li, C. H., Yeh, H. L., Dung, P. V. T., Jiang, K. C., Chen, W. H., Li, H. R., Huang, J., & Chen, W. Y. (2024). Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer. Cancer Letters, 598, 217090. https://doi.org/10.1016/j.canlet.2024.217090

Vancouver

Liu YN, Liu MK, Wen YC, Li CH, Yeh HL, Dung PVT, et al. Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer. Cancer Letters. 2024;598:217090. doi:10.1016/j.canlet.2024.217090

BibTeX
@article{Liu2024,
  author = {Liu, Yen-Nien and Liu, Ming-Kun and Wen, Yu-Ching and Li, Chien-Hsiu and Yeh, Hsiu-Lien and Dung, Phan Vu Thuy and Jiang, Kuo-Ching and Chen, Wei-Hao and Li, Han-Ru and Huang, Jiaoti and Chen, Wei-Yu},
  title = {Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {598},
  pages = {217090},
  doi = {10.1016/j.canlet.2024.217090}
}
Kostenlos starten →